56985-40-1
基本信息
9,11-二脫氧基-11Α,9Α-亞甲基環(huán)氧前列腺素 F2Α
9,11-二脫氧基-9Α,11Α-亞甲基環(huán)氧前列腺素 F2Α溶液
9,11-DIDEOXY-11Α,9Α-EPOXYMETHANOPROSTAGLANDIN F2Α
9,11-Methanoxy-PGH2
9,11-Methanoepoxy PGH2
11α,9α-Epoxymethanoprostaglandin H2
U-46619 - CAS 56985-40-1 - Calbiochem
9,11-DIDEOXY-11ALPHA,9ALPHA-EPOXYMETHANO
4-alpha,5-beta(z),6-alpha(1e,3s*)))-r-(1-alph
9,11-dideoxy-11α,9α-epoxymethanoprostaglandin f2α
9,11-dideoxy-11A,9A-epoxymethano-*prostaglandin F
9,11-DIDEOXY-9ALPHA,11ALPHA-METHANOEPOXY PGF2ALPHA
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
常見(jiàn)問(wèn)題列表
U-46619是一種PGH2類(lèi)似物,可以用作血栓烷A2(TP)受體激動(dòng)劑,影響人類(lèi)血管平滑肌的促有絲分裂生長(zhǎng)。U 46619是穩(wěn)定的血栓烷A2模擬物,是H2內(nèi)過(guò)氧化物前列腺素的類(lèi)似物,用作血管收縮劑和血栓烷受體激動(dòng)劑。
TXA2
U-46619 (1 nM-10 μM) causes platelets shape change and aggregation in a concentration-dependent manner, and with EC
50
s of 0.58 μM and 0.013 μM for aggregation and shape change, respectively.
U-46619 (10 nM-10 μM) increases internal Ca
2+
concentration ([Ca
2+
]i) and activates phosphoinositide (PI) hydrolysis in a concentration-dependent manner with a similar concentration-dependency.
U-46619 (3 nM-10 μM) also activates GTPase concentration-dependently in the membranes derived from platelets.
U-46619 improves the differentiation efficiency of human induced pluripotent stem cells into endothelial cells by activating both p38MAPK and ERK1/2 signaling pathways.
U-46619 (5 μg/kg; i.v.) increases blood pressure in male spontaneously hypertensive rats (SHR).
Animal Model: | 12-15 weeks-old male and female SHR |
Dosage: | 5 μg/kg |
Administration: | Intravenous injection |
Result: | Induceed a significant increase of MABP after 1 min in male SHR. |
報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱(chēng) | CAS號(hào) | 包裝 | 價(jià)格 |
2024/11/08 | HY-108566 | 9,11-二脫氧基-9Α,11Α-亞甲基環(huán)氧前列腺素 F2Α溶液 U-46619 | 56985-40-1 | 1mg(28.5mM * 100μL in Methyl acetate) | 3300元 |
2024/08/19 | HY-108566 | 9,11-二脫氧基-9Α,11Α-亞甲基環(huán)氧前列腺素 F2Α溶液 U-46619 | 56985-40-1 | 5mg(28.5mM * 500μL in Methyl acetate) | 9900元 |